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Abstract 
Drug delivery systems including chemical, physical and biological agents that enhance the 
bioavailability, improve pharmacokinetics and reduce toxicities of the drugs. Carrier eryth-
rocytes are one of the most promising biological drug delivery systems investigated in recent 
decades. The bioavailability of statin drugs is low due the effects of P-glycoprotein in the 
gastro-intestinal tract as well as the first-pass metabolism. Therefore in this work we study 
the effect of time, temperature as well as concentration on the loading of pravastatin in human 
erythrocytes to be using them as systemic sustained release delivery system for this drug. 
After the loading process is performed the carriers' erythrocytes were physically and cellulary 
characterized. Also, the in vitro release of pravastatin from carrier erythrocytes was studied 
over time interval. Our results revealed that, human erythrocytes have been successfully 
loaded with pravastatin using endocytosis method either at 25
oC or at 37
oC. The loaded 
amount at 10 mg/ml is 0.32mg/0.1 ml and 0.69 mg/0.1 ml. Entrapment efficiency is 34% and 
94% at 25
oC and 37
oC respectively at drug concentration 4 mg/ml. Moreover the percent of 
cells  recovery  is  87-93%.  Hematological  parameters  and  osmotic  fragility  behavior  of 
pravastatin loaded erythrocytes were similar that of native erythrocytes. Scanning electron 
microscopy demonstrated that the pravastatin loaded cells has no change in the morphology. 
Pravastatin releasing from carrier cell was 83% after 23 hours in phosphate buffer saline and 
decreased to 72% by treatment of carrier cells with glutaraldehyde. The releasing pattern of 
the drug from loaded erythrocytes obeyed first order kinetics. It concluded that pravastatin is 
successfully entrapped into erythrocytes with acceptable loading parameters and moderate 
morphological changes, this suggesting that erythrocytes can be used as prolonged release for 
pravastatin. 
Key words: drug delivery, erythrocytes, pravastatin, osmotic fragility 
Introduction 
The  statin  drugs  are  used  in  the  treatment  of 
hypercholesterolemia;  moreover,  these  drugs  have 
pleiotropic effect, so that they are used in the treat-
ment  of  many  diseases  such  as  osteoporosis,  Alz-
heimer disease, organ transplantation, stroke and di-
abetes  [1].  Administration  of  statins  by  oral  rout  is 
associated with several problems including diarrhea, 
constipation, indigestion and nausea [2]. Also the bi-
oavailability of these drugs is low due the effects of 
cytochrome  and  P-glycoprotein  (Pgp)  in  the  gas-
tro-intestinal tract as well as the first-pass metabolism 
in  the  liver  [3].  Therefore,  the  increased  dosage  of 
statin  drugs  is  usually  used  to  obtain  the  desired 
therapeutic efficacy but increasing the dose of these 
drugs  may  exaggerate  the  side  effects  on  the  liver, 
kidney and muscular tissue [3].  Int. J. Med. Sci. 2011, 8 
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The  pharmacologically  active  form  of  pravas-
tatin is open hydroxyl-acid so that its hydrophilicity is 
markedly higher than that of other statins. The oral 
bioavailability of this statin is low due to degradation 
in the stomach and incomplete absorption [4]. There-
fore, several strategies are used for improvement both 
pharmacokinetics  and  pharmacodynamic  properties 
of statins including inhibition of the metabolism [5], 
administration of statins with certain juices [6] or in-
hibition of Pgp [3].  
Unfortunately  these  strategies  are  frequently 
associated with increase the risk of side effects of the 
statins  [3,7].Therefore  the  developments  of  novel 
pharmaceutical formulations are used as alternative 
approaches to improve the bioavailability and thera-
peutic efficacy these drugs [8-10]. Several studies have 
been suggested different pharmaceutical devices like 
nanoparticles,  microparticles  [11],  and  drug-loaded 
erythrocytes [12, 13]. 
Carrier  erythrocytes  are  one  of  the  biological 
drug delivery systems investigated in recent decades. 
They  are  biologically  compatible  and  have  large 
volumes; therefore, they are well suited to be used as 
drug carriers. Additionally, they can be used as sub-
stitute biological carriers such as liposomes or nano-
particles that have been used for the encapsulation of 
therapeutic  agents  [14].  According  to  the  desired 
therapeutic strategy erythrocytes are used either as a 
carrier for sustained release of the drugs or as carriers 
to deliver and target drugs to specific organs [15]. 
Therapeutic agents can be loaded in erythrocytes 
either by physical methods such as endocytosis and 
osmosis-based systems or by chemical perturbation of 
the  erythrocytes  membrane  [16].  Endocytosis  is  the 
process by which cells absorb molecules by engulfing 
them. It is used by all cells of the body because most 
substances important to them are large polar mole-
cules  that  cannot  pass  through  the  hydrophobic 
plasma  or  cell  membrane  [17].  Drug  loading  into 
erythrocyte by endocytosis is more preferable when 
they used sustained released carriers, because it has 
minimal  effects  on  erythrocytes  structure  and  mor-
phology.  The  substances  to  be  entrapped  into  the 
erythrocytes should have a degree of water solubility 
and  resistance  to  degradation  within  erythrocytes 
[18]. Certain drugs have been entrapped in erythro-
cytes  by  endocytosis,  including  vinblastine,  chlor-
promazine,  hydrocortisone,  propranolol,  tetracaine, 
retinol, and primaquine [16, 19].  
The current work aims to study the encapsula-
tion of pravastatin in human carrier erythrocytes by 
endocytosis method. The entrapment efficiency of the 
drug at different times, temperatures as well as dif-
ferent initial concentrations of this statin was investi-
gated. The hematologic parameters and osmotic fra-
gility of the loaded carrier erythrocytes were evalu-
ated. Additionally, the in vitro release of pravastatin 
from carrier erythrocytes was measured over time. 
Materials and methods 
Materials 
The chemicals used in this study were pravas-
tatin sodium(SPIMACO, Riyadh, Saudi Arabia), NaCl 
(Merck,  Germany),  KCl  (Fluka  chemie  AGCH), 
Na2HPO4·12H20  (BDH-GPRTm),  KH2PO4  (Merck, 
Germany),  MgCl2·6H2O  (Avonchem  Limited), 
MgSO4.7H2O  (Sigma  Chemical  Co.,  St.  Louis,  Mo), 
Glucose  (Panreac),  NaHCO3  (Panreac),  adenosine 
5-triphosphate  (Spectrum  chemical  MFG.  CORP) 
glutaraldehyde  and  acetonitrile  (HPLC  grade)  and 
methanol from acquired from (BDH). All remaining 
chemicals were of analytical grade. 
Instrumentation 
A  Coulter®  AC.T  diffTM  hematology  analyzer 
(Beckman  Coulter,  Inc.,  Brea,  CA,  USA);  a  Spectro 
UV-Vis Split Beam PC, model UVS-2800 (Labomed, 
Inc.,  Culver  City,  CA,  USA);  Chromatography  was 
performed by reversed phase ultra performance liq-
uid chromatography (UPLC). Acquity® (UPLC) sys-
tem, using Acquity® UPLC BEH C18 column (1.7 μm, 
2.1 mm x 50 mm) obtained from Waters (Waters Inc., 
Bedford, MA, USA). Water bath (Julabo SW22), Jen-
cons  375H  sonicator,  Hettic  EBA  20  and  Hettic 
MIKRO 20(Germany) centrifuges were used in these 
investigations. 
Preparation of erythrocyte suspension 
The  blood  specimens  were  collected  from  ap-
parently healthy donors not suffered from acute and 
chronic diseases. Informed consent was obtained from 
each of the donors. Blood samples were collected in 
heparinized vacutainers and centrifuged for 5 min at 
5000  rpm.  The  plasma  and  the  buffy  coat  were  re-
moved by aspiration. Erythrocytes were washed three 
times in cold phosphate buffer saline (PBS) with cen-
trifugation for 5 min at 5000 rpm [20, 21]. The exper-
imental protocol was approved by the research center 
ethics committee of King Saud University College of 
Pharmacy, Riyadh, Saudi Arabia. 
Pravastatin loading procedures  
The  hematocrite  of  washed  erythrocytes  was 
adjusted by PBS to 45%. In 2 ml eppendorff tubes, 400 
µl of suspension are added to 400 µl of PBS containing 
the known concentration of the drug and 2.5 mmol of 
ATP, 2.5 mmol MgCl2 and 2.5 mmol of CaCl2, gently 
mixing  to  avoid  hemolysis  and  incubation  for  15 Int. J. Med. Sci. 2011, 8 
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minutes at room temperature. The erythrocytes sus-
pension is centrifuged for 5 min at 5000 rpm and the 
supernatant  is  discarded.  The  packed  erythrocytes 
was washed 2 times in cold BPS with centrifugation 
for 5 min at 5000 rpm [22]. 
Study the effect of concentration 
To determine the effect of drug concentration on 
loading  efficiency  we  use  different  drug  concentra-
tions (2 mg, 4 mg, 8 mg, and 10 mg) for all selected 
incubation times, and compare results to obtain the 
more suitable concentration for loading process which 
produce most excellent loading parameters [23]. 
 Study the effect of time 
The  effect  of  time  on  loading  efficiency  and 
loading process was done for the previous concentra-
tions for different times (15, 30, 60, 120 minutes) and 
compare the results [24]. 
Study the effect of temperature 
The loading process was done at 25oC and 37oC 
for the previous different times and concentrations. 
Loading parameters 
To evaluate the final erythrocyte carriers, three 
indices were defined as loading parameters (loaded 
amount, entrapment efficiency and cell recovery) [25]. 
Loaded amount 
 The total amount of pravastatin entrapped in 0.1 
ml of the final packed erythrocytes. 
Efficiency of entrapment 
The percentage of the loaded amount of pravas-
tatin to the total amount of that added during the en-
tire loading process. 
Cell recovery 
The percentage ratio of the hematocrite value of 
the final loaded cells to that of the initial packed cells, 
both measured using equal suspension volumes. 
In vitro characterization of pravastatin loaded erythrocytes 
Hematological Indices 
To  determine  the  effect  of  loading  process  on 
erythrocytes,  normal  erythrocytes,  erythrocytes  sus-
pended in PBS, and pravastatin-loaded erythrocytes 
were counted. The mean corpuscular volume (MCV: 
mean cell volume), the mean corpuscular hemoglobin 
(MCH:  average  hemoglobin  content  per  each  cell), 
and  the  mean  corpuscular  hemoglobin  content 
(MCHC: hemoglobin content per 100 ml of cell vol-
ume) were measured using Coulter® LH 780 hema-
tology analyzer [24]. 
Determination of osmotic fragility behavior of loaded 
erythrocytes 
Erythrocytes resistance against lysis as a result of 
the  osmotic  pressure  changes  of  their  surrounding 
media was evaluated. Twenty five l of erythrocyte 
sample was added to each of a series of 2.5 ml saline 
solutions containing 0.0 to 0.8 g% of NaCl. After gen-
tle mixing and standing for 15 min at room tempera-
ture, the erythrocyte suspensions were centrifuged at 
5000 rpm for 5 min. The absorbance of the superna-
tant  was  measured  at  540  nm  [26].  The  absorbance 
percentage  released  hemoglobin  was  expressed  as 
percentage absorbance of each sample in correlation 
to a completely lysed sample prepared by diluting of 
packed cells of each type with 1.5 ml of distilled wa-
ter. Osmotic fragility was studied for each drug con-
centration.  
In vitro releasing study  
The release of pravastatin as well as hemoglobin 
from carrier erythrocytes were determined as follow-
ing,  1  ml  of  packed  drug-loaded  erythrocytes  was 
diluted to 10 ml using PBS the suspension was mixed 
thoroughly  by  several  gentle  inversions.  Then,  the 
mixture was divided into ten 0.5 ml portions in 1.5 ml 
eppendorf tube. The samples were rotated vertically 
while incubated at 37◦C. At the beginning of the test 
and also at 0.25, 0.5, 1, 2, 8, 20, and 23 h intervals, one 
of the samples was harvested and then centrifuged at 
3000 for 5 min. One hundred μl of the supernatants 
were  separated for  drug  assay.  In  addition,  the  ab-
sorbance of a 0.3 ml portion of the supernatant was 
determined  at  540  nm  using  a  spectrophotometer. 
Hemoglobin release were determined in reference to a 
completely lysed sample[15]. The release of drug was 
studied also in plasma and in PBS after addition of 
glutaraldehyde. 
Pravastatin assay by UPLC  
A reversed phase UPLC method was developed 
and used throughout the study for pravastatin assay. 
The mobile phase in this method consists of acetoni-
trile and water with ratio 35:65, the flow rate was 0.5 
ml/min. The analyte separation was carried out using 
C18 column under temperature 40º C using UV de-
tector at 237 nm. 
 To determine the amount of loaded pravastatin, 
the erythrocyte pellets were hemolysed by addition of 
equal volume of distilled water with strong shaking to 
ensure erythrocyte hemolysis. The proteins were pre-
cipitated by addition of 1ml methanol, mixed well and 
vortexed for 15 minute and then centrifuged at 13000 
rpm for 15 minutes. The supernatant is taken and fil-
tered using 0.22 Millipore disposable filters and then Int. J. Med. Sci. 2011, 8 
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complete the volume to 5ml by water. 1µl of filtrate 
was injected to the UPLC.  
Scanning electron microscopy (SEM)  
A JEOL JSM-6380 LA scanning electron micro-
scope (Jeol Ltd., Tokyo, Japan) equipped with a digital 
camera,  at  20  kV  accelerating  voltage  was  used  to 
evaluate  the  morphological  differences  between 
normal  and  pravastatin  loaded  erythrocytes.  Both 
normal and 8 mg/ml pravastatin -loaded erythrocyte 
samples were processed as follows. After the samples 
were fixed in buffered glutaraldehyde, the aldehyde 
medium  was  drained  off.  The  cells  were  rinsed  3 
times for 5 min in phosphate buffer and post-fixed in 
osmium  tetroxide  for  1  h.  The  samples  were  then 
rinsed  with distilled  water and dehydrated using a 
graded  ethanol  series:  25,  50,  75,  100,  and  another 
100%, each for 10 min. The samples were rinsed in 
water,  removed,  mounted  on  studs,  sputter-coated 
with gold, and then viewed using SEM [25]. 
Statistical analysis 
The  statistical  differences  between  native  and 
loaded  erythrocytes  were  analyzed  by  one  way 
ANOVA  followed  by  the  Bonferroni  multiple  com-
parison  test,  using  PASW  Statistics  18  Software,  v. 
5.01  (SPSS  Software,  Inc.).  The  results  with  p<0.01 
were considered statistically significant. 
Results and discussion 
Analysis method validation 
The new invented method of pravastatin sodium 
extraction and assay in erythrocytes using UPLC was 
validated according to FDA guidelines. Recovery of 
extraction  method  was  (96%-108%),  the  analysis 
method  was  selective  to  the  drug  with  accuracy 
(98%-103%) and precision (0.3-6.4). All the tested pa-
rameters were in acceptable levels. 
Encapsulation of pravastatin in human erythrocytes 
The current work studies effect of time, temper-
ature as well as drug concentration on the process of 
pravastatin loading into human erythrocytes by en-
docytosis method as trial to obtain pravastatin pro-
longed  release  system.  The  results  show  that  the 
highest  level  of  pravastatin  loaded  on  erythrocytes 
was attained using 10 mg/ml of the drug, at 37oC and 
2 hours incubation time. While at 25oC the maximum 
drug loading is attained after 1hour.  
This  result  in  agreement  with  previous  study 
demonstrated the increase in the cell membrane ac-
tivity upon temperature increase till reach optimum 
temperature 37oC [27]. Also this find is supported by 
another study shows that, endocytosis process is de-
creased  by  decreasing  temperature[17],  Therefore 
drug loading at 37oC is greater than at 25oC. Table 1 
display  the  effect  of  pravastatin  concentration  and 
incubation time on the amount of pravastatin loaded 
on human carrier erythrocytes at 25oC while table 2 
display the same parameters at 37oC. 
 
Table 1, Effect of pravastatin concentration and incubation 
time on the amount of pravastatin loaded on human carrier 
erythrocytes at 25
oC by endocytosis 
Drug  concentra-
tion(µg/ml) 
Drug incubation times 
15 min.  30 min.  60 min.  120 
min. 
2× 103  292 ± 
15.5 
395 ± 
40.1* 
532 ± 
39.1* 
544 ± 
23.0 
4× 103  415 ± 
20.0# 
971 ± 3 
7.1*# 
1366 ± 
63.5*# 
1286 ± 
36.5# 
8× 103  627 ± 
26.8# 
2006 ± 
36.6*# 
2561 ± 
111*# 
2499 ± 
46.0# 
10× 103  706 ± 
28.5# 
2352 ± 
42.0*# 
3211 ± 
66.5*# 
3170 ± 
134# 
Data were tested by one-way analysis of variance and represented 
as mean ± SD. Six samples in each group (N = 6). Bonferroni multi-
ple comparison tests using SPSS software was performed to deter-
mine differences between mean values. * Significantly different 
according to time at p < 0.01, # significantly different according to 
concentration at p < 0.01. 
 
 
Table 2, Effect of pravastatin concentration and incubation 
time on the amount of pravastatin loaded on human carrier 
erythrocytes at 37
oC by endocytosis 
Drug  concentra-
tion(µg/ml) 
Drug incubation times 
15 min.  30 min.  60 min.  120 min. 
2× 103  223 ± 
23.5 
1047 ± 
127* 
1317 ± 
70.0 
1663 ± 
245 
4× 103  489 ± 
19.0# 
1795 ± 
13.7*# 
3031 ± 
297*# 
3788 ± 
339*# 
8× 103  907 ± 
14.5# 
2074 ± 
267* 
4169 ± 
222*# 
5540 ± 
479*# 
10× 103  1047 ± 
33.5# 
2725 ± 
241*# 
4690 ± 
178*# 
6900 ± 
88.0*# 
Data were tested by one-way analysis of variance and represented 
as mean ± SD. Six samples in each group (N = 6). Bonferroni multi-
ple comparison tests using SPSS software was performed to deter-
mine differences between mean values. * Significantly different 
according to time at p < 0.01, # significantly different according to 
concentration at p < 0.01 
 
 
The presence of agents like tonicity as well as an 
energy source stimulate the endocytosis [28]. In our 
demonstration, the presence of calcium ions as well as 
ATP  stimulates  the  endocytosis  of  pravastatin  by Int. J. Med. Sci. 2011, 8 
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erythrocytes. This is supported by the observation of 
Schrier  et  al.,  which  reported  that  the  calcium  ions 
and energy  source  stimulate drug uptake by eryth-
rocytes  through  membrane  invagination  and  for-
mation  of  endocytotic  vacuoles  [29].  The  drugs  in-
duced endocytosis is dependent on the persistence of 
erythrocyte energy sources [30].  
Also,  the  results  of  this  demonstrated  that  the 
loading of pravastatin into erythrocytes was directly 
proportional with increase of drug concentration in 
the incubation medium, in the 2-10 mg/ml concen-
tration range. This finding is in concurrence with re-
sults reported by Millan [24], and Hamidi [25, 31]. 
Loading parameters 
Loaded amount 
The loaded amounts of pravastatin at 25ºC and 
37ºC  were  determined;  at  25  ºC  the  highest  loaded 
amount was 0.32 mg while it is 0.69 mg at 37 ºC. These 
loaded  amounts  are  suitable  to  pravastatin  dosing 
upon  reinjection  of  low  volumes  of  drug  loaded 
erythrocytes to the host body. This demonstration was 
stated in another studies by Bossa  [32] and Hamidi 
[15, 25], according to similar results. 
Loading efficiency at 25
oC 
The effect of concentration and incubation time 
on the percent of drug loading is shown in figures 1 
and  2  at  25ºC  and  at  37ºC.  The  percent  is  of  drug 
loading was started from 15% after 15 minutes upon 
using drug concentration 2 mg at 25oC, and decreased 
upon  increasing  concentration.  The  higher  percent 
was 34% that given at 4 mg after 60 minutes. 
Loading efficiency at 37ºC 
The results obtained at 37oC were much better 
than the one obtained at 25oC. The loading efficiency 
reaches 94% at 4mg after 120 minutes, while decrease 
upon increasing concentration. This loading efficiency 
is  better  than  that  obtained  in  primaquine  loading 
study as comparison [33].  
Cell recovery 
A cell recovery of loading process was 87-93%, 
this is practically better than the recovery results of 
other studies such as primaquine and enalaprilat [33, 
34]. This result is may be an evident to the quite effect 
of loading process on erythrocytes and/or protective 
effect of pravastatin as investigated in previous study 
stated  that  the  pravastatin  protect  erythrocytes 
against oxidative damage induced by drugs [35]. 
 
 
 
Figure 1, Effect of pravastatin incubation time and drug concentration on the percent of pravastatin loading on human 
carrier erythrocytes at 25
oC
 by endocytosis. The highest loading efficiency obtained when concentration 4 mg/ml is used for 
incubation time 1 hour. Data is expressed as mean ± SD, Six samples in each group (N = 6). Int. J. Med. Sci. 2011, 8 
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Figure 2, Effect of pravastatin incubation time and drug concentration on the percent of pravastatin loading on human 
carrier erythrocytes at 37
oC
 by endocytosis. The highest loading efficiency obtained when concentration 4mg/ml is used for 
incubation time 2 hours. Data is expressed as mean ± SD, Six samples in each group (N = 6). 
 
Table 3, Hematological parameters of control erythrocytes and loaded erythrocytes obtained with different concentra-
tions of pravastatin (mg/ml) 
  Control  Sham encapsulated  2 mg/ml  4 mg/ml  8mg/ml  10 mg/ml 
Hct (%)  51.6 ± 2.04  44.9 ± 0.21  45.9 ± 1.49  45.3 ± 3.68  48.0 ± 2.20  51.6 ± 2.04 
MCV (fl)  84.1 ± 0.32  82.3 ± 0.57  83.6 ± 0.47  82.9 ± 1.25  83.4 ± 0.46  81.2 ± 0.36* 
MCH (pg)  28.2 ± 0.68  28.2 ± 0.03  27.6 ± 0.20  27.7 ± 0.06  27.8 ± 0.15  27.3 ± 0.10** 
MCHCH 
(gm/dl) 
33.5 ± .035  34.2 ± 0.28  33.0 ± 0.46  33.4 ± 0.38  33.4 ± 0.29  33.6 ± 0.27 
Data were tested by one-way analysis of variance and represented as mean ± SD. Three samples in each group (N = 3). Bonferroni multiple 
comparison tests using SPSS software was performed to determine differences between mean values at (P ≤ 0.01).* significantly different 
from the control at p < 0.01, ** significantly different from the control at (p< 0.05). Mean corpuscular volume (MCV), Mean corpuscular he-
moglobin (MCH), Mean corpuscular hemoglobin concentration (MCHC).  
 
 
 
In vitro characterization of pravastatin loaded erythrocytes 
Hematological Indices 
The  hematological  parameters,  such  as  MCV, 
MCH and MCHC were characterized. These parame-
ters  determine  the  influence  of  the  encapsulation 
process on the hematological properties of the eryth-
rocytes [24]. Table 3 represent the mean hematological 
parameters  of  the  pravastatin  loaded  erythrocytes 
obtained  with  different  pravastatin  concentrations 
and values for the same cells before the loading pro-
cedures (the control cells) and after loading process 
but without using drug(sham encapsulated).  
The results show non-significant change in he-
matological  parameters  is  observed  except  MCV  at 
higher  concentrations  (10  mg).  From  these  data 
pravastatin loading into erythrocytes occurs either by 
encapsulation  or  binding  to  the  cell  membrane[36] 
and  also  the  loading  procedure  does  not  affect  the 
MCV. This finding is in agreement with previous re-
port[34].  Non-significant  change  in  both  MCH  and 
MCHC  can  be  explained  by  pravastatin  preserve  a 
physical  and/or  functional  barrier  of  erythrocyte, 
therefore  prevent  hemoglobin  loss  from  carrier 
erythrocytes.  These  predictions  are  supported  the 
SEM analysis data and osmotic fragility that will dis-
cussed later. Int. J. Med. Sci. 2011, 8 
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Osmotic fragility behavior of pravastatin loaded eryth-
rocytes 
Osmotic fragility determines the susceptibility of 
erythrocytes to osmotic lysis in respect to serial dilu-
tion of NaCl. The data obtained shows that there is no 
significant difference in the osmotic fragility of loaded 
erythrocyte at 2, 4, 8 mg/ml pravastatin when com-
pared to that of unloaded erythrocytes (Table 4).  
 
Table 4, Erythrocyte osmotic fragility of unloaded eryth-
rocytes and erythrocytes loaded with 8, 4 and 2 mg/ml 
pravastatin. Values are percent hemolysis in corresponding 
salt concentrations 
NaCl %  Control  2 mg  4 mg  8 mg 
0.80  1.30 ± 0.66  0.54 ± 0.01  0.92 ± 0.01  1.19 ± 0.01 
0.70  5.35 ± 1.34  0.74 ± 0.01  1.23 ± 0.01  2.80 ± 0.02 
0.60  12.3 ± 1.97  7.26 ± 0.07  9.53 ± 0.06  8.99 ± 0.07 
0.50  29.7 ± 3.42  15.0 ± 0.03  17.2 ± 0.04  15.2 ± 0.04 
0.45  56.5 ± 3.50  55.6 ± 0.08  71.2 ± 0.09  73.2 ± 0.10 
0.40  74.1 ± 3.04  73.5 ± 0.12  88.7 ± 0.14  94.0 ± 0.17 
0.35  80.45 ±1.56  76.8 ± 0.11  93.9 ± 0.09  94.1 ± 0.16 
0.30  84.4 ± 4.14  77.4 ± 0.11  95.8 ± 0.12  97.7 ± 0.12 
0.20  89.6 ± 4.60  78.6 ± 0.12  97.7 ± 0.10  99.0 ± 0.02 
0.10  96.8 ± 4.80  80.8 ± 0.5  100 ± 0.11  100 ± 0.03 
0.00  100 ±0.05  100 ± 0.01  100 ± 0.11  100 ± 0.03 
Data were tested by one-way analysis of variance and represented 
as mean ± SD. Three samples in each group (N = 3). Bonferroni 
multiple comparison tests using SPSS software was performed to 
determine differences between mean values at (P ≤ 0.01).  
 
 
Several studies reported the effect of drugs on 
fragility behavior of erythrocytes. Hamidi et al., stated 
that osmotic fragility of loaded erythrocytes is lower 
than unloaded cells [34]. On contrast, another study 
revealed that osmotic fragility of carrier erythrocytes 
is  higher  than  unloaded  cells  [37].  In  The  present 
study, the behavior of pravastatin loaded erythrocytes 
towards  serial  concentration  of  NaCl  (0.0-  0.8%)  is 
similar to native unloaded cells. From the results of 
osmotic  fragility  and  hematological  parameters,  it 
seems that pravastatin may preserve the physiological 
and  morphological  characters  of  erythrocytes  mem-
brane. This suggestion was supported by our previ-
ous study stated that this statin preserve of erythro-
cytes fragility and morphology during drug loading 
[35].  
Scanning electron microscopy 
In Figure 3, the scanning electron micrographs 
erythrocytes of drug loaded erythrocytes by our se-
lected  method  at  5000  magnifications.  The  loading 
process resulted in different stages of normal bicon-
cave shape and without changes in morphology. This 
result shows that the loading process is not aggressive 
and/or the drug has no deleterious effects on eryth-
rocyte shape. The  maintenance of carrier cells  mor-
phology similar to native cells gives the opportunity 
for carrier erythrocytes to life span like native  [19]. 
This result suggested that loaded erythrocytes can be 
used  for  sustained  release  of  pravastatin.  This  as-
sumption  is  supported  by  previous  findings  which 
recommended that the use of carrier erythrocytes as 
extended release system for prednisolone due to the 
minimal  effect  of  drug  loading  on  the  erythrocytes 
morphology[13].  
Pravastatin release 
Figure 4 shows that the pravastatin release pat-
tern from loaded erythrocytes in PBS, plasma and PBS 
after using glutaraldehyde as a membrane stabilizer. 
Also  the  figure  shows  the  hemoglobin  release.  The 
releasing curves of pravastatin show 2 release phases, 
the first is rapid release phase and the second is slow 
sustained release phase with hemoglobin release sim-
ilar pattern. Pravastatin release in PBS is rapid process 
compared to release in plasma and after glutaralde-
hyde treatment. It reaches 83% in PBS after 23 hours, 
and then decreased to 72% after treat with glutaral-
dehyde after 23 hours. While in plasma it reaches only 
72% after 23 hours. These results are comparable to 
results  reported  on  similar  polar  drugs  including 
gentamicin[38],  enalaprilat  [39]  and  heparin  [40]. 
Hemoglobin release kinetics is belonged to zero order 
pattern  while  pravastatin  is  belonged  to  first  order 
kinetics in both two phases. The two phases may be, 
first, due to coupling the drug to erythrocyte mem-
brane [36] as predicted before. Second, it may be due 
to the presence of some efflux transporters in eryth-
rocyte membrane mediating drug active efflux out of 
the cell [15].  
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Figure 3, Scanning electron micrograph of pravastatin loaded erythrocytes by endocytosis. A) Control erythrocytes, B) 
Pravastatin loaded erythrocytes, morphological features like the control one. Magnification is X5000. 
 
Figure 4, Percent of pravastatin and hemoglobin release from loaded erythrocytes in PBS and plasma. Data were tested by 
one-way analysis of variance and represented as mean ± SD. Three samples in each group (N = 3). Bonferroni multiple 
comparison tests using SPSS software was performed to determine differences between mean values at (P ≤ 0.01). 
Conclusion 
The  endocytosis  method  is  less  destructive  to 
erythrocytes  and  preserves  the  cells  fragility  and 
morphology  like  the  native  ones.  Furthermore, 
pravastatin has no deleterious effect on erythrocyte as 
indicated by osmotic fragility test and SEM. The re-
sults  revealed  that  pravastatin  was  loaded  success-
fully on human erythrocytes with acceptable loading 
parameters.  Pravastatin  releases  from  loaded  eryth-
rocytes  obeying  first  order  kinetics  and  it  needs  24 
hours to release 71% of loaded drug in plasma. These 
results suggested that erythrocyte is suitable carrier 
for retarded released pravastatin. However, the rela-
tive impacts of different in vitro findings on the over-
all in vivo drug delivery efficacy of these cellular car-
riers remain to be evaluated during the future in vivo 
studies. 
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